Esperion Therapeutics Inc (NASDAQ:ESPR) currently has a daily average trading volume of 5.55M but it saw 3603453 shares traded in last market. With a market cap of 428.56M USD, the company’s current market price of $2.17 came rising about 0.69 while comparing to the previous closing price of $2.16. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.94 and as low as $1.58. In the recent trading on the day, stock has struck highest price mark of $2.145 while lowest mark touched by it was $2.25.
Taking a look at 20-day trading activity of Esperion Therapeutics Inc (ESPR) gives us an average price of $2.79, while its current price level is -44.80% below from 52-week high level whereas it is 37.66% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.40 while that of 200 days or SMA-200 reads an average of $2.24. A closer look into the stock’s movement over the week reveals that its volatility is standing at 12.14% during that period while stretching the period over a month that increases to 12.85%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 41.72 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Goldman which initiated the stock as “Neutral” in its note to investors issued on December 18, 2024, recommending a price target of $4 for it. BofA Securities issued its recommendations for the stock as it downgraded the price target for the stock is $2.50.
Over the week, ESPR’s stock price is moving -14.71% down while it is -9.75% when we observe its performance for the past one month. Year-to-date it is -27.26% down and over the past year, the stock is showing a downside performance of -7.05%.
The company is expected to be releasing its next quarterly report in January, for which analysts forecasted an EPS of -0.13 while estimate for next year EPS is -0.29. In next quarter, company is expected to be making quarterly sales of $53.3M as analysts are expecting the sales for current fiscal year at $327.16M and seeing the company making $400.66M in sales next year. Moreover, analysts are in estimates of $62.14M for current-quarter revenue.
Currently, Esperion Therapeutics Inc’s total number of outstanding shares is 195.44M. Company’s return on investment (ROI) stands at -58.53%. It has a 10.02 of forward P/E ratio. Stock’s beta reads 1.04. Stock has a price to sale or P/S ratio amounts to 1.45. Its return on asset (ROA) is -32.41% on average.
